natgillin/translations-raw huggingface dataset:
Laboratorios Hipra, S.A. (CIAMER) Carretera C-63, km 48.300, Polígono Industrial El Rieral 17170 Amer (Girona) Spain 
Laboratorios Hipra, S.A. (CIAMER) Carretera C-63, km 48.300,
** RED80: Rabbit effective dose in 80% of the animals (serology). 
** RED80: djelotvorna doza u kunića, u 80% životinja (serološki nalaz).
Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon. 
HITNO je potreban stručni kirurški pregled koji može zahtijevati preventivnu inciziju i ispiranje injiciranog područja, napose u području jagodice prsta ili tetiva.
EXP Once opened, use within a 10-hour period, stored at 15-25 ºC. 
Jednom otvoreno pakovanje, primijeniti u roku od 10 sati, čuvano između 15-25 ºC.
Batch{number} 
Lot {broj}
Shelf life after first opening the immediate packaging: 10 hours stored at 15 °C to 25 ºC. 
Rok valjanosti poslije prvog otvaranja unutarnjeg pakovanja: 10 sati čuvano između 15 °C do 25 ºC.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PET vials (10 ml, 50 ml) and glass vials (2 ml, 10 ml, 50 ml) 
PET ampule (10 ml, 50 ml) i staklene ampule (2 ml, 10 ml, 50 ml)
Liquid paraffin: 18.2 mg 
18,2 mg Pomoćna tvar:
S. aureus (CP8) strain SP 140 inactivated, expressing slime associated antigenic complex (SAAC) > 50 RED80 (In 80% of the animals). 
S. aureus (CP8) soj SP 140 inaktiviran, koji izražava kompleks antigena pridružen sluzi (SAAC) > 50 RED80 (u 80% životinja). parafin, tekući: 18,2 mg benzilni alkohol: 21 mg
EU/2/08/092/009 1 PET vial of 25 doses EU/2/08/092/010 1 PET vial of 125 doses 
16. BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET EU/2/08/092/001 1 staklena bočica s 1 dozom EU/2/08/092/002 10 staklenih bočica s 1 dozom EU/2/08/092/003 20 staklenih bočica s 1 dozom
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary 
4.10 Predoziranje (simptomi, hitni postupci, antidoti), ako je nužno Nakon primjene dvostruke doze cjepiva nisu zapažene nuspojave osim onih navedenih u dijelu 4.6.
Shelf life after first opening the immediate packaging: 10 hours stored at 15 ºC to 25 ºC. 
Rok valjanosti poslije prvog otvaranja unutarnjeg pakovanja: 10 sati čuvano između 15 ºC i 25 C.
STARTVAC emulsion for injection for cattle 
STARTVAC emulzija za injekcije za goveda.
No adverse reactions other than those mentioned in section “Adverse reactions” were observed after the administration of a double dose of vaccine. 
Nakon primjene dvostruke doze cjepiva nisu zapažene nuspojave osim onih navedenih u dijelu “Nuspojave”.
THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN” 
11. POSEBNE MJERE PRI ČUVANJU Čuvati izvan pogleda i dosega djece.
PACKAGE LEAFLET FOR: STARTVAC emulsion for injection for cattle 
UPUTA O VMP: STARTVAC emulzija za injekciju za goveda.
Tel: (+48) 22 642 33 06 
HIPRA POLSKA Sp.z.o.o. Tel: (+48) 22 642 33 06
HIPRA UK AND IRELAND, Ltd. Tel: (+44) 0115 912 4320 
Hipra Italia S.r.l. Tel: ( +39) 030 7241821
Hrvatska 
KARENCIJE
Type I colourless glass vials of 3, 10 and 50 ml. 
I od 3, 10 i 50 ml.
- Cardboard box with 1 and 10 glass vials of 25 doses. 
- Kartonska kutija s 1 i 10 staklenih bočica s 25 doza.
- Cardboard box with 1 and 10 glass vials of 5 doses. 
- Kartonska kutija s 1 i 10 staklenih bočica s 5 doza.
WITHDRAWAL PERIODS 
ROK VALJANOSTI
- Cardboard box with 1 PET vial of 125 doses. 
- Kartonska kutija s 1 PET bočicom s 125 doza.
Escherichia coli J5 inactivated ............................................................................. > 50 RED60* Staphylococcus aureus (CP8) strain SP 140 inactivated, expressing slime associated antigenic complex (SAAC) ............. …………………………………………… > 50 RED80** 
Escherichia coli J5 inaktivirana .......................................................................... > 50 RED60 *
Cardboard box with 20 glass vials of 1 dose. 
- Kartonska kutija s 20 staklenih bočica, s 1 dozom.
Hipra Italia S.r.l. 
United Kingdom HIPRA UK AND IRELAND, Ltd.
Escherichia coli (J5) inactivated .......................................................................... > 50 RED60* Staphylococcus aureus (CP8) strain SP 140 inactivated, expressing slime associated antigenic complex (SAAC)........................................................................ ........................................ > 50 RED80** * RED60: Rabbit effective dose in 60% of the animals (serology). 
Staphylococcus aureus (CP8) soj SP 140 inaktiviran, koji izražava kompleks antigena pridružen sluzi (SAAC) .................. …………………………………………… > 50 RED80 **
Special warnings for each target species: The whole herd should be immunised. 
12. POSEBNO(A) UPOZORENJE(A) Posebna upozorenja za svaku od ciljnih vrsta životinja:
Cardboard box with 10 glass vials of 5 doses. 
- Kartonska kutija s 10 staklenih bočica, s 5 doza.
HIPRA POLSKA Sp.z.o.o. 
Deutschland HIPRA DEUTSCHLAND GmbH
Cardboard box with 1 glass vial of 5 doses. 
- Kartonska kutija s 1 staklenom bočicom, s 5 doza.
Cardboard box with 10 glass vials of 1 dose. 
- Kartonska kutija s 10 staklenih bočica, s 1 dozom.
Pack sizes: - Cardboard box with 1, 10 and 20 glass vials of 1 dose. 
- Kartonska kutija s 1, 10 i 20 staklenih bočica s 1 dozom.
Store and transport refrigerated. 
11. POSEBNI UVIJETI ČUVANJA Čuvati i prevoziti rashlađeno Zaštititi od svjetla.
Cardboard box with 1 glass vial of 1 dose. 
- Kartonska kutija s 1 staklenom bočicom, s 1 dozom.
- Cardboard box with 1 PET vial of 25 doses. 
- Kartonska kutija s 1 PET bočicom s 25 doza.
- Cardboard box with 1 PET vial of 5 doses. 
- Kartonska kutija s 1 PET bočicom s 5 doza.
Special precautions for use in animals: Vaccinate healthy animals only. 
Posebne mjere opreza prilikom primjene na životinjama:
Danmark 
SPAIN
5 years 
5 godina.
An additional 5 deaths were reported subsequently. 
Naknadno je prijavljeno još 5 smrtnih slučajeva.
Date of first authorisation: 14th November 2016 
Datum prvog odobrenja: 14. studeni 2016
It is not possible to determine whether these events are related directly to these factors or to other factors. 
Ne može se utvrditi jesu li ti događaji izravno povezani s tim faktorima rizika ili s drugim faktorima.
- if you are taking riociguat. 
- ako uzimate riocigvat.
1047 Budapest Hungary 
1047 Budimpešta Mađarska
An updated RMP should be submitted: • At the request of the European Medicines Agency; 
Ažurirani RMP treba dostaviti: na zahtjev Europske agencije za lijekove;
Elderly (≥65 years) 
Stariji (≥65godina)
Paediatric population (1 year to 17 years) 
Pedijatrijska populacija (1 do 17 godina)
The causes of deaths were related to PAH. 
Uzroci smrti bili su povezani s PAH-om.
Most, but not all, of these patients had pre-existing cardiovascular risk factors. 
U većine, ali ne i svih tih bolesnika već su postojali kardiovaskularni faktori rizika.
Your doctor may tell you to reduce the dose over a few days before stopping completely. 
Liječnik će Vam možda reći da smanjite dozu tijekom nekoliko dana prije nego što potpuno prestanete uzimati lijek.
Tmax was estimated at approximately 1 hour and was almost independent from body weight. 
Procjenjuje se da Tmax iznosi približno 1 sat i da je gotovo neovisan o tjelesnoj težini.
You should be aware of how you react to the medicine before you drive or use machines. 
Trebali biste znati kako reagirate na ovaj lijek prije nego što počnete voziti ili upravljati strojevima.
- take medicines for erectile dysfunction. 
- uzimate lijekove za erektilnu disfunkciju
Sildenafil is rapidly absorbed. 
Sildenafil se brzo apsorbira.
MedDRA system organ class (V.14.0) 
MedDRA klasifikacija organskih sustava (V.14.0)
95% confidence interval 
Procijenjena razlika Interval pouzdanosti 95%
Children Granpidam should not be given to children below 1 year of age. 
Djeca Granpidam se ne smije davati djeci mlađoj od 1 godine.
The improvement in 6MWD was apparent after 4 weeks of treatment and this effect was maintained at weeks 8 and 12. 
Poboljšanje 6MWD-a bilo je vidljivo nakon 4 tjedna liječenja i taj je učinak bio održan u 8. i u 12. tjednu.
Tell your doctor if you are taking any of these medicines. 
Obavijestite svog liječnika ako uzimate neki od tih lijekova.
n=29 for placebo group 
n = 29 za skupinu koja je primala placebo
In cases of overdose, standard supportive measures should be adopted as required. 
U slučaju predoziranja, po potrebi je potrebno primijeniti standardne suportivne mjere.
90 tablets 300 tablets 15x1 tablet 90x1 tablet 300x1 tablet 
90 tableta 300 tableta 15x1 tableta 90x1 tableta 300x1 tableta
Cardiovascular risk factors 
Kardiovaskularni faktori rizika
Clinical efficacy as measured by 6-minute walk distance could be less in elderly patients. 
Klinička djelotvornost mjerena 6-minutnom postignutom udaljenošću hodom može biti manja u starijih bolesnika.
Alpha-blockers 
Alfa-blokatori
Other medicines and Granpidam 
Drugi lijekovi i Granpidam
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove:
The duration of treatment was 12 weeks. 
Liječenje je trajalo 12 tjedana.
In the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance. 
U slučaju erekcije koja traje dulje od 4 sata, bolesnik treba zatražiti hitnu medicinsku pomoć.
The safety and efficacy of sildenafil in children below 1 year of age has not been established. 
Sigurnost i djelotvornost sildenafila u djece mlađe od 1 godine nisu ustanovljene.
Many events were reported to occur during or shortly after sexual intercourse and a few were reported to occur shortly after the use of sildenafil without sexual activity. 
Prijavljeno je da su mnogi od tih događaja nastupili tijekom ili ubrzo nakon spolnog odnosa, a nekoliko ih je prijavljeno ubrzo nakon uzimanja sildenafila bez seksualne aktivnosti.
Granpidam can cause a serious increase in the effects of these medicines. 
Granpidam može uzrokovati ozbiljno pojačanje učinaka tih lijekova.
If you are pregnant, or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. 
Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku ili ljekarniku za savjet prije nego uzmete ovaj lijek.
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy and embryonal/foetal development. 
Ispitivanja na životinjama ne ukazuju na izravne ili neizravne štetne učinke na trudnoću i razvoj embrija/fetusa.
Wessling Hungary Kft Fòti ùt 56., Budapest 1047, Hungary or 
Wessling Hungary Kft Fòti ùt 56., Budimpešta 1047, Mađarska ili
What Granpidam is and what it is used for 
Što je Granpidam i za što se koristi
If you are taking riociguat or are unsure tell your doctor. 
Ako uzimate riocigvat ili niste sigurni obratite se svom liječniku.
Granpidam passes into your breast milk at very low levels and would not be expected to harm your baby. 
Granpidam se izlučuje u majčino mlijeko u vrlo malim količinama i ne očekuje se da bi mogao naškoditi Vašem dojenčetu.
Tablets should be taken approximately 6 to 8 hours apart with or without food. 
Tablete treba uzimati u razmaku od oko 6 do 8 sati, s hranom ili bez nje.
Its effect is more potent on PDE5 than on other known phosphodiesterases. 
Njegov učinak na PDE5 snažniji je nego na druge poznate fosfodiesteraze.
Sage House, 319 Pinner Road, North Harrow, Middlesex HA1 4HF, United Kingdom or 
Sage House, 319 Pinner Road, North Harrow, Middlesex, HA1 4HF Ujedinjeno Kraljevstvo ili
Physicians should advise patients who forget to take Granpidam to take a dose as soon as possible and then continue with the normal dose. 
Liječnici trebaju savjetovati bolesnicima koji zaborave uzeti Granpidam da uzmu dozu što prije, a zatim nastave s uobičajenom dozom.
If you forget to take Granpidam, take a dose as soon as you remember, then continue to take your medicine at the usual times. 
Ako ste zaboravili uzeti Granpidam, uzmite dozu čim se sjetite, a zatim nastavite uzimati lijek u uobičajeno vrijeme.
The duration of treatment was 16 weeks. 
Liječenje je trajalo 16 tjedana.
The subsequent effect on efficacy is unknown. 
Nije poznat posljedični učinak na djelotvornost.
Serious adverse events were reported in 94 (41%) of the 229 subjects receiving sildenafil. 
Ozbiljne nuspojave prijavljene su u 94 (41%) od 229 ispitanika koji su primali sildenafil.
These reports included dizziness and lightheadedness, but not syncope. 
Te su prijave uključivale omaglicu i ošamućenost, no ne i sinkopu.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
Zahtjevi za podnošenje periodičkih izvješća o neškodiljvosti za ovaj lijek definirani su u referentnom popisu datuma EU (EURD popis) predviđenom člankom 107.c stavkom 7. Direktive 2001/83/EZ i svim sljedećim ažuriranim verzijama objavljenima na europskom internetskom portalu za lijekove.
The results of the main analysis (combined dose groups versus placebo) were not statistically significant (p = 0.056) (see Table 2). 
Rezultati glavne analize (kombinirane doze sildenafila u odnosu na placebo) nisu bili statistički značajni (p = 0,056) (vidjeti Tablicu 2).
Of the 278 patients randomised, 277 patients received at least 1 dose of study drug. 
Od 278 randomiziranih bolesnika, 277 ih je primilo najmanje 1 dozu ispitivanog lijeka.
Granpidam can cause dizziness and can affect vision. 
Granpidam može izazvati omaglicu i može utjecati na vid.
What Granpidam is and what it is used for What you need to know before you take Granpidam How to take Granpidam 
Što je Granpidam i za što se koristi Što morate znati prije nego počnete uzimati Granpidam
The use of sildenafil in other forms of PAH is not recommended. 
Ne preporučuje se primjena sildenafila u drugim oblicima PAH-a.
- if you have recently had a stroke, a heart attack or if you have severe liver disease or very low blood pressure (<90/50 mmHg). 
- ako ste nedavno imali moždani udar ili srčani udar, ili ako imate tešku bolest jetre ili vrlo nizak krvni tlak (< 90/50 mmHg).
Do not stop taking Granpidam unless your doctor tells you to. 
Nemojte prestati uzimati Granpidam ako Vam tako ne kaže liječnik.
If you take more medicine than you have been told to take contact your doctor immediately. 
Ako uzmete više lijeka nego što Vam je preporučeno, odmah se javite svom liječniku.
What you need to know before you take Granpidam 
Što morate znati prije nego počnete uzimati Granpidam
Higher doses should not be used in children. 
U djece se ne smiju primjenjivati veće doze.
37 deaths occurred prior to a decision taken by the Data Monitoring Committee to down titrate subjects to a lower dosage, based on an observed mortality imbalance with increasing sildenafil doses. 
37 smrtnih slučajeva nastupilo je prije odluke Povjerenstva za praćenje podataka o smanjivanju doze u ispitanika, na temelju opažene neravnoteže u smrtnosti kod povećanja doza sildenafila.
This is consistent with ritonavir's marked effects on a broad range of P450 substrates. 
To je u skladu s izraženim učincima ritonavira na široki spektar supstrata P450.
Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential, toxicity to reproduction and development. 
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza, genotoksičnosti, kancerogenosti te reproduktivne i razvojne toksičnosti.
Use of sildenafil with bosentan 
Primjena sildenafila s bosentanom
However to avoid the possible occurrence of sudden clinical deterioration during withdrawal, a gradual dose reduction should be considered. 
Međutim, kako bi se izbjeglo eventualno naglo pogoršanje kliničkog stanja tijekom ukidanja terapije, treba se razmotriti postupno smanjivanje doze.
Concomitant use with other PDE5 inhibitors 
Istovremena primjena s drugim PDE5 inhibitorima
Not known sudden hearing loss 
često vrtoglavica nepoznato iznenadni gubitak sluha
Across the short-term and long-term studies, the overall duration of treatment from start of double-blind for individual subjects ranged from 3 to 3129 days. 
Tijekom kratkotrajnog i dugotrajnog ispitivanja, ukupno trajanje liječenja od početka dvostruko slijepog ispitivanja za pojedine pacijente kretalo se u rasponu od 3 do 3129 dana.
Actual doses administered within a group were dependent on body weight (see Section 4.8). 
Stvarne primijenjene doze unutar pojedine skupine su ovisile o tjelesnoj težini bolesnika (vidjeti dio 4.8).
No clinical data are available regarding adverse events in breast-fed infants, but amounts ingested would not be expected to cause any adverse effects. 
Nisu dostupni klinički podaci povezani sa štetnim događajima u dojenčadi, ali ne očekuje se da će unesene količine prouzročiti ikakve nuspojave.
Non-clinical data revealed no special hazard for humans based on conventional studies of fertility (see section 5.3). 
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja utjecaja na plodnost (vidjeti dio 5.3).
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. 
Bolesnici s rijetkim nasljednim problemima nepodnošenja galaktoze, nedostatkom Lapp laktaze ili malapsorpcijom glukoze i galaktoze ne bi trebali uzimati ovaj lijek.
Studies in animals have shown toxicity with respect to postnatal development (see section 5.3). 
Ispitivanja na životinjama pokazala su toksičnost za postnatalni razvoj (vidjeti dio 5.3).
A downward dose adjustment to 20 mg twice daily should be considered after a careful benefit-risk assessment only if therapy is not well-tolerated. 
Snižavanje doze na 20 mg dva puta na dan treba razmotriti nakon pažljive procjene koristi i rizika samo ako bolesnik dobro ne podnosi terapiju.
The most common adverse reactions reported across the duration of the short-term and long-term studies were generally similar to those observed in the short-term study. 
Najčešće nuspojave prijavljene tijekom trajanja kratkotrajnog i dugotrajnog ispitivanja bile su u pravilu slične nuspojavama koje su opažene u samom kratkotrajnom ispitivanju.
In vitro studies 
Ispitivanja in vitro
There are no adequate and well controlled studies in lactating women. 
Ne postoje odgovarajuća i dobro kontrolirana ispitivanja provedena među dojiljama.
Treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. 
Liječenje pedijatrijskih bolesnika u dobi od 1 do 17 godina s plućnom arterijskom hipertenzijom.
Mean pulmonary systolic blood pressure decreased by 9%. 
Srednja vrijednost plućnog sistoličkog krvnog tlaka snižena je za 9%.
Granpidam brings down blood pressure in the lungs by widening the blood vessels in the lungs. 
Granpidam snižava krvni tlak u plućima tako što proširuje krvne žile u plućima.
There are no data on the interaction of sildenafil and non-specific phosphodiesterase inhibitors such as theophylline or dipyridamole. 
Nema podataka o interakciji sildenafila i nespecifičnih inhibitora fosfodiesteraze kao što su teofilin ili dipiridamol.
These additional blood pressure reductions were of a similar magnitude to those seen when sildenafil was administered alone to healthy volunteers. 
Ova dodatna sniženja krvnog tlaka bila su podjednako velika kao i kada se sildenafil primjenjivao sam u zdravih dobrovoljaca.
Taking more Granpidam than you should may increase the risk of known side effects. 
Uzimanje više lijeka Granpidam nego što je potrebno može povećati rizik od poznatih nuspojava.
Pharmacotherapeutic group: Urologicals, Drugs used in erectile dysfunction, ATC code: G04BE03 
Farmakoterapijska skupina: Urologici; lijekovi koji se primjenjuju kod erektilne disfunkcije, ATK oznaka: G04BE03.
Sildenafil had no significant effect on atorvastatin exposure (AUC increased 11%), suggesting that sildenafil does not have a clinically relevant effect on CYP3A4. 
Sildenafil nije imao značajan učinak na izloženost atorvastatinu (AUC povećan za 11%), što upućuje na to da sildenafil nema klinički značajan učinak na CYP3A4.
Peak VO2 was assessed 1 year after the start of the placebo-controlled study. 
Vršni VO2 ocijenjen je nakon godinu dana od početka placebom kontroliranog ispitivanja.
Patients should not take a double dose to compensate for the missed dose. 
Bolesnici ne smiju uzeti dvostruku dozu kako bi nadoknadili propuštenu dozu.
Physicians should advise patients what to do in the event of postural hypotensive symptoms. 
Liječnici trebaju uputiti bolesnike kako trebaju postupiti u slučaju simptoma posturalne hipotenzije.
Sildenafil plasma concentration half-life values were estimated to range from 4.2 to 4.4 hours for a range of 10 to 70 kg of body weight and did not show any differences that would appear as clinically relevant. 
Poluvijek koncentracije sildenafila u plazmi procjenjuje se na između 4,2 i 4,4 sata za raspon tjelesne težine od 10-70 kg te nisu uočene razlike koje bi mogle biti od kliničkog značaja.
The adverse reactions profile seen in this paediatric study was generally consistent with that in adults (see table above). 
Profil nuspojava opažen u ovom pedijatrijskom ispitivanju bio je uglavnom u skladu s onim zabilježenim u odraslih osoba (vidjeti prethodnu tablicu).
In general, any dose adjustment should be administered only after a careful benefit-risk assessment. 
Općenito, bilo kakva prilagodba doze treba se primijeniti samo nakon pažljive procjene koristi i rizika.
There was a doubling of the Cmin compared to healthy volunteers. 
Vrijednosti Cmin bile su dvostruko veće nego u zdravih dobrovoljaca.
In single dose volunteer studies of doses up to 800 mg, adverse reactions were similar to those seen at lower doses, but the incidence rates and severities were increased. 
U ispitivanjima na dobrovoljcima s primjenom jedne doze do 800 mg nuspojave su bile slične onima opaženima pri nižim dozama, ali se povećala stopa incidencije i težina.
Do not use this medicine after the expiry date which is stated on the carton and blister after ‘EXP'. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza oznake "Rok valjanosti" i "EXP".
In vivo studies 
Ispitivanja in vivo
Limited data suggest that the abrupt discontinuation of sildenafil is not associated with rebound worsening of pulmonary arterial hypertension. 
Ograničeni podaci upućuju na to da nagli prekid primjene sildenafila nije povezan s povratnim pogoršanjem plućne arterijske hipertenzije.
- if you are taking a medicine to treat fungal infections such as ketoconazole or itraconazole or medicines containing ritonavir (for HIV). 
- ako uzimate lijekove za liječenje gljivičnih infekcija, kao što su ketokonazol ili itrakonazol, ili lijekove koji sadrže ritonavir (za liječenje HIV infekcije).
If you take more Granpidam than you should 
Ako uzmete više lijeka Granpidam nego što ste trebali
Sildenafil has no effect on visual acuity or contrast sensitivity. 
Sildenafil nema učinka na oštrinu vida niti na osjetljivost na kontraste.
Sildenafil has moderate influence on the ability to drive and use machines. 
Sildenafil umjereno utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Protein binding is independent of total drug concentrations. 
Vezanje za proteine ne ovisi o ukupnoj koncentraciji lijeka.
In order to minimise the potential for developing postural hypotension, patients should be haemodynamically stable on alpha-blocker therapy prior to initiating sildenafil treatment. 
Kako bi se smanjila mogućnost razvoja posturalne hipotenzije, bolesnici trebaju biti hemodinamički stabilni na terapiji alfa-blokatorom prije započinjanja liječenja sildenafilom.